IXSBF fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
InNexus Biotechnology, Inc. develops commercial opportunities based on the field of monoclonal antibodies, naturally occurring proteins that fight infection and disease, utilizing its proprietary DXL and Transmab technologies with following focus areas: ophthalmology, dermatology, and oncology. The company was founded by Alton Charles Morgan on September 5, 1997 and is headquartered in Vancouver, Canada.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
IXSBF does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company